Trial Profile
A randomized, single blinded, placebo-controlled, multi-centre, phase II study of lapatinib in patients with locally advanced squamous cell carcinoma of the head and neck
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Antineoplastics
- Indications Head and neck cancer; Squamous cell cancer
- Focus Biomarker; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 27 May 2011 New source identified and integrated (European Clinical Trials Database).
- 27 May 2011 Actual initiation date changed from Mar 2006 to 30 Nov 2005 as reported by European Clinical Trials Database.
- 14 Sep 2008 Results reported at ESMO 2008.